Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.

Matteo CesaroniLoqmane SeridiMatthew J LozaJessica SchreiterKristen SweetCarol FranksKeying MaAshley OrillionKim CampbellRobert M GordonPatrick BraniganPeter LipskyRonald van VollenhovenBevra H HahnGeorge C TsokosMarc ChevrierShawn RoseFrédéric BaribaudJarrat Jordan

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

While not diminishing a potential role of IL-23, these serum biomarker assessments indicate that IL-12 blockade has an important role in the mechanism of action of ustekinumab treatment in patients with SLE.

Keyphrases

systemic lupus erythematosus
dendritic cells
combination therapy
human health
risk assessment
replacement therapy
smoking cessation